this is big pharma? >> as i noted, manufacturers excise tax and also applies to importers and those industries tend to be larger firms. >> now, $170 billion we do not have unpaid for. loss ofotal revenue these provisions would be $170 billion. >> the gentleman from arizona was making to the case we were to pass this bill and big pharma was to receive this $170 billion windfall that consumers would see benefit from this because their prices would go down. is there anything in this bill that requires a dollar for dollar gift back to consumers? is no requirement. the economic analysis that i discussed based on market economics. >> so, in fact if this were to theirnd big pharma got to $170 billion, we don't know if they reduce prices by similar amount? clarify one thing so it does not get confused as we discussed further, the 170 be a dollars -- $170 billion -- >> understand. law,ere's no guarantee in chance to pass an increase or decrease in excise taxes through to final consumers. >> we have no way of know

manus: donald trump tweeted late in regard toernoon pharma stocks. new system where there will be industry.n in the even though you got to gdp , there's no japan doubt about it, trump is unseating the market. many futures are down for the fifth day in a row. the longest run of losses since the presidential election. anna: much more on the asian growth story coming up. now it's bloomberg first word news. we will talk about the gdp numbers from japan in just a moment. donald trump met with the over thembassador engagement between trump allies in the kremlin, despite claims that he had zero involvement with russell -- russian affiliate -- russian officials during the campaign. revelations last week that five members of his team tookontact before trump office. meanwhile, president trump has been throwing his weight behind the house republican plan to as one obamacare, even republican senator declared it dead on arrival in the senate. trump had a meeting yesterday to rally them behind the deal, setting up an unexpectedly close alliance between the preside

for five months, pharma was a toxic sector. but as i mentioned earlier, the group has made a big turnaround in 2017, and this is what's important. lang thinks it can continue. so let's go through these names one by one, starting with pfizer's weekly chart. i haven't looked at this one in ages. if you look at the last six months, lang points out pfizer has been making a bullish w pattern. this is the kind of bottom formation that suggests the rally in this stock is just getting started. when i did get rich carefully, i found the w pattern to be the strongest pattern in terms of what a stock was about to do. yeah, that's right. this is sleepily old pfizer and bob langthys it's got the best chart of the bunch. it's made a series of higher highs. that's an oscillator which measures the level of buying and selling pressure in a stock, giving ah sense of what the big institutional investors are dog. it's just about to turn positive. you can see that, right? lang says the last time that happened, well, guess what? pfizer rallied 20%.

these scientists at neuro pharma put neurons, those brain cells, in two petri dishes.ed the same neuropeptides that are in cebria. and the one on the left, they did not. the neurons on the left are alive, but they're not really thriving. they're just there. now look at the neurons on the right. they are thriving. they're robust. you can actually see the new branches growing, reaching out, making new connections. this is really revolutionary. this is nature right there telling you the truth. not hype, real science. in fact, dr. thomas crook, a former taskforce chairman at the national institutes of mental health said, and i quote: and he's just one of the growing community of renowned doctors and researchers who recognize the remarkable effect of cebria. this is the very first product that contains what we call neurotrophic factors or growth factors. and these growth factors actually helps the neurons grow. what we have been able to show is a significant improvement in a placebo-controlled study, a significant improvement in memory tests. cebria users can expect to see,

. >> reporter: the city of everett has now filed a lawsuit against the maker of the drug, purdue pharma. the lawsuit claims purdue knowingly, recklessly and negligently supplied it to pharmacies and physicians and monitored the illegal trafficking of its pills, knew high volumes were being distributed and didn't share the informations with law enforcement. everett's mayor -- >> i believe it's about greed, and they need to be held accountable to make our community high. >> reporter: purdue pharma denied our request for an interview but says it has a strong record of working with law enforcement and information it's provided in some cases has led to convictions. in a statement, they told us the lawsuit paints a completely flawed and inaccurate portrayal of the events that led to the crisis in everett. he says the lawsuit is about rebuilding his community. >> they give corporations a bad name, and they've affected lives. people have died. and they need to be held accountable. and i believe they will be. >> reporter: purdue also told us they look forward to presenting the facts in court. ev

the xlv, that is a large cap pharma in there. that one double topped at 76.s down 3.5% since then. i think you can sell that on rallies. i don't think it breaks out above 76. >> rates went higher on expectations that fiscal syst stimulus the economy would improve, rates go higher. if this health care plan somehow puts a -- handy caps a tax -- handy capps any tax reform and fiscal stimulus goes by the way side, the rates can rally. it will start going the other way. what does that mean? it means tlt can rally. back to you, mel. >>> up next, final word from the traders for the week. stay tuned. hey nicole. hey! i just wanted to thank your support team for walking me through my first options trade. we only do it for everyone gary. well, i feel pretty smart. well, we're all about educating people on options strategies. well, don't worry, i won't let this accomplishment go to my head. i'm still the same old gary. wait, you forgot your french dictionary. oh, mucho gracias. get help on options trading with thinkorswim, only at td ameritrade. what?pony neighing] hey

reporter: the city of everett has now filed a lawsuit against the maker of the pain killer, purdue pharmalawsuit claims purdue knowingly, recklessly, and/or negligently surprised oxycontin to suspicious physicians and pharmacies and it alleges purdue monitored the illegal trafficking of its pills, knew high volumes were being distributed, and didn't share the information with law enforcement. everett's mayor ray stephanson. >> i believe it's about greed, and they need to be held accountable to make our community whole. >> reporter: purdue pharma declined our request for an interview but says it has a strong record of working with law enforcement and information its provided in some drug cases has led to convictions. in a statement, purdue told us the lawsuit, "paints a completely flawed and nakerate portrayal of events that led to the crisis in everett." stephanson says the lawsuit is about rebuilding his community. >> they give corporations a bad name, and they've affected lives. people have died, and they need to be held accountable, and i believe they will be. >> reporter: purdue also

hitting pharma hard, down 20% before it was halted in a decision in which forward pharma has been fighting with biogen. they are popping on this news on the win here on this drug. it essentially would have ruled that biogen would have had to pay a 10% to forward pharma on this drug. this looking like they won't have to do that. maybe not popping so much because biogen preemptively settled with forward pharma. a lot of movers on patent decisions in the biotech space today. >> meg, thank you very much. >>> president trump meeting with manufacturing ceos at the white house today. also set to sign two new executive orders on trade. commerce secretary wilbur ross ratcheting up the trade war rhetoric as michelle referenced earlier and he did it right here on cnbc. >>> tyler, soaring optimism this afternoon during the meeting with those executives 93% of the companies surveyed at the national manufacturers association say they're feeling good about the outlook and that's a record high driving up sentiment is a prospect of tax reform, infrastructure, and deregulation. here is the president in the

>> i don't care for horizon pharma, especially pharma is not my cup of team.'m going to have to say take it off the table. how about joshua in my home state of new jersey, joshua. >> caller: how you doing, jim? >> i'm doing good. how about you? >> caller: good, buddy. i'm about 150% on amd so far. i was wondering with the recent pullback, do you see that as a buying opportunity? >> you got to wait until all the hot money came in. all the hot money was in for that chip that came out and the reviews were okay. let the stock go down to 12 and a quarter and pull the trigger. let's go to steve in new jersey, steve. >> caller: hey, booyah, jim. >> booyah. >> caller: i have a question for you. boeing. bought at 172. wondering if i should take profits or -- >> it wouldn't be so bad to take half off the table. that thing has been too much of a horse and i like boeing a great deal. and that, ladies and gentlemen, is the conclusion of the lightning round! [ buzzer ] >> announcer: the lightning round is sponsored by td ameritrade. >>> rangers win? geez. >> paper towels. t

eli lilly has the best diabetes franchise of all the big pharma names. it's certainly the most stable way to invest in this terrible but definitely long-lasting trend. much more "mad money" ahead. what do allergan, jpmorgan, and wynn resorts all have in common? i'll reveal it and tell you how it could help you make money. then it's a texas bank that survived all the downturns in the energy sector. how did colin frost do it? i'm going to sit down with the ceo. and does fang still have its bite in this market? yes, i'm eyeing facebook, amazon, netflix, and alphabet to see if these stocks could still pull away from here. stick with cramer. various: (shouting) heigh! ho! ( ♪ ) it's off to work we go! woman: on the gulf coast, new exxonmobil projects are expected to create over 45,000 jobs. and each job created by the energy industry supports two others in the community. altogether, the industry supports over 9 million jobs nationwide. these are jobs that natural gas is helping make happen, all while reducing america's emissions. energy lives here. all while

about greed, and they need to be held accountable to make our community whole. >> reporter: purdue pharmaerview but says it has a strong history of working with law enforcement and information it's provided in some cases has led to convictions. in a statement, they told us the lawsuit paints a completely flawed and inaccurate portrayal of the crisis in everett. he says the lawsuit is about rebuilding his community. >> they give corporations a bad name. and they've affected lives. people have died. and they need to be held accountable, and i believe they will be. >> reporter: everett's mayor says if they win any money for purdue, they'll use it for treatment programs and law enforcement. >>> the federal government has extended the deadline for companies to submit bids to filled the first section of president trump's wall along the mexico border. the deadline was yesterday, but the interior department still has not decided what kind of wall it wants or where it will go. meanwhile, towns all along the border are threatening to sue to stop it. david begnaud is in brownsville, texas, where the

banks and pharma stocks seem to be where the money is rotating into. back to the pharma story.how you what is happening. this is the index point. novo nordisk, unilever, standard chartered, so the banks are fairly mixed up. some of the miners softening as well. novo nordisk, the big drop. reason i really like the imap function and i use it a lot on a daily basis to see where industries are moving around each particular index. i would like to take a quick look at currencies now. options show investors are becoming more pessimistic on the greenback versus the euro and the yen. the dollar has almost erased its gains from the so-called trump reallyprogrowth policies have yet to materialize. there was a massive rally from november. guy: i have a chart. tv.t: #bt 7047 is the number if you want to access that from your bloomberg. that was when the dollar index reached a high point. it has since come down a little more than 5%. we're looking at a gain of less than 2% since trump was elected president. guy: where do we go from here? how important is this health care bill? are we going t

sales pharma down 8/10 of 1%.r, one of the best-performing currencies, rising as china suggested, north korea suspended nuclear plans, up 2/10 of 1%. thevery strong week from won. china's number two telecom maker is fine for violating u.s. restrictions on the sale of american technology to iran. will plead guilty and pay as much as $1.2 billion. we have more from our managing editor, live in tokyo. peter, tell the details of the settlement. mentioned, zte has agreed to pay as much as 1.2 billion dollars. they are guilty to violating export rules of the united states and interfering with the investigation. the u.s. has tried to make an example out of zte. you saw government officials, including wilbur ross, come out aggressively to make an example of the company to show what they will do when companies violate the laws. was contrite, admitted they had done wrongdoing. they had a long list of changes that would make inside the company to scrutinize more carefully how they will respond to these allegations. billion.y

network as ae the platform for exporting pharma gets. -- pharma goods.you make 15% yesterday? some investors did. they searched to their seven-year high. we will be talking that and speculation about more middle east mergers. this is bloomberg. ♪ ♪ you are watching bloomberg, i am david e less in hong kong. tracy: i am tracy alloway in abu dhabi. they have search that are highest level despite to their investment bank, comes after the chairman said he was in merger talks with a much bigger entity. for more on this we are joined by bloomberg markets reporter. really a stunning move in the capital yesterday. up 15%. walk us through what is driving that rise. we have a lot of talk and speculation. >> this is a story that has been focused on speculation. since last year in june when abu dhabi financial group brought -- bought the nation -- it in shuaa. they will make it big again as it used to be in the past. the company was previously owned by the government of dubai. it has been a wild that they have said that they would buy assets here in the ue. yesterda

. >> let's have a further discussion about the pharma provision i would think that most every family if not every family on this committee has benefited from pharmaceuticals. sole i raise this without any hostility indeed, quite be opposite the much of the basic research has come from nih for my beloved wife once worked in greece struggle to get money for research for nih and it is also true the pharmaceutical companies have invested their own talents and resources once there is a development to bring into fruition. >> it is contrary to the of far met position with the affordable care act was put together just to read this if i might we believe comprehensive health care reform will benefit patients in the future of america. that is why we have been involved in the public policy debate -- debate over a year in support the final health care reform bill in the amendment filed with the reconciliation legislation for so essentially what the majority is doing is to give back the pharmaceutical industry essentially what they agreed to 10 years ago and that is a serious mistake. so now to di

the landscape, pharma and med tech, there is a fragmentation.s of players have weaker positions, losing positions even in one or two or three or four categories and that creates an opportunity for more consolidation, for people to consolidate a leading position and to jettison losing positions in therapeutic areas. for that reason we see a lot of opportunity as well, not just for integration. there is still room for substantial consolidations. david: 15 was a record year and 16 was close to it. there has been a lot already. >> certainly for an organization that has done a big deal, it takes some time to digest that. we would expect that for individual companies to do multiple massive deals in succession. there have also been changes in merger rules that make large but ifls less attractive you go back to your basic business school economics, we don't really see anything like that in pharma. it is massively fragmented. alix: he to get your perspective. dale stafford, partner at bain and company. we continue our conversation with roger altman. this

this is a big car run -- a big pharma. >> and those industries tend to be larger one-hundred $70 billion that we don't have. >> the total revenue loss for these provisions is $170 billion. >> the gentle man from arizona was making the case if we were to pass this bill and a big pharma was to receive this $170 billion windfall that consumers would see a benefit from this because their prices would go down. is there anything in this bill that requires a dollar for dollar give back to the consumers but. >> there is no requirement that economic analysis that i have discussed it is based on market economics. >> if this were to pass and big pharma got there $170 billion we don't know if they would reduce prices by a similar amount. >> bill $170 billion. >> there is no guarantee in lot of the market economics it will tend to pass an increase or decrease of the excise tax through to the final consumer. >> we have no way to know that will happen. vat of dollars the bill now why would we think with this windfall that somehow they would be like the good fairy to deliver that to the consumer quick.

. >>> shares in roche rally as a key trial shows that a combination of two of the pharma group's oncology drugs can reduce the occurrence of breast cancer. >>> cementing growth. shares of lafareholcim rise after the cementmaker posts better than expected earnings for the fourth quarter. ceo eric olsen says the company will benefit from u.s. infrastructure spending under president trump. >> we're ideally positioned in the u.s. we as lafareholcim, we believe we stand to benefit very well from these investments going forward. a trillion in investments and infrastructure is a real commitment. >>> building bust. travis perkins slides to the bottom of the stoxx 600 after reporting a 67% fall in pretax profit. >>> disappearing app snap getting ready to make a lasting impression on the market preparing to go public just a day after the dow jumps over 300 points to close above 21,000. >>> good morning. let's kick off with some corporate news. shares in roche trading at nine-month highs after the success of a key cancer drug drill, a combination of her-ciptin an per-jeta together with chemotherapy

this isn't the first time trump trashed the pharma industry. hard in the winter and spring last year, not as hard as hillary and reiterated the view and the man of the year interview for time magazine. second, the president shocker is not there. if he wants to crack down on drug pricing, he needs help from congress and that might be difficult to get because drug companies are incredibly powerful in washington and systematically frustrated any attempts by the government to restrain pricing in my lifetime. they may be the most powerful lobby in the capital. third, the truth is the only way to really rain in drug prices is the single payer health care system where pharmaceutical companies have no choice but to bow down or be kicked to the cub. buy the one with the lower offer and cut the other out. in that sense, single payer the government will be basically determining prices, and that's how it works in most developed countries. now single payer has long been a dream of many democrats, but right now the republicans are in charge and this kind of

>> it's interesting the pharma companies that oppose opioids oppose it. they think it would help. in fact, the correlation you would expect, marijuana has been realized as being legal sized oep yoits are less serious. the thing about opioids, there's a technical point which i'm not a doctor, not that sort of doctor, but what seems to happen is people get addicted. doctors are good at prescribing the stuff and no one knows how to get someone unaddicted. that's too strong a statement but we have very, very poor of getting people unaddicted. people fight it and they get themselves unaddicted so they are not taking this stuff anymore. and then what happens is they relapse. and if you relapse and you take the dosage you were taking just before you relaxed, you will die because you lose the adaptation that the body has built up, to taking larger and larger quantities of opioids which is what you need to control your pain. if you take marijuana and you may get addicted to marijuana but it doesn't do that to you. and it's also like alcohol, you may be addicted to alcohol and may be an alc

the work is part of a large project called pharma sea. the divers are defending to areas where little research has been done before. they hope to discover microorganisms that can develop other novel drugs. >> let's with driver -- with the divers. bash let's see what they divers brought for us. sponges are very interesting for the bacteria. reporter: back in the lab, the microorganisms are grown and tested to find out whether they can kill bacteria. >> there's the problem that many bacteria have become resistant to every antibiotic known to man , so we need new antibiotics. reporter: antibiotic resistance is on the rise because the drugs are overused. if researchers failed to develop new antibiotics, around 10 million people could die every year from untreatable infections. the international research team has no time to lose. brent: business news now and helen is with us. is the end of cheap money nine? helen: certainly decision-making time for central banks and lots of meetings of central banks regarding monetary policy from britain to ja

does this bill have any effect that you can see on biotech or pharma? >> the bill does a couple things. number one, it repeals a tax that is $30 billion over ten years. that's bigger than medical device tax. additionally, it doesn't touch anything on drug pricing which is really the potential policy is to hold back handful of these stocks from when candidate hillary clinton tweeted about it. we feel really optimistic about where it will be. we also believe repatriation, if that happens as part of tax reform. you could see a lot of cash flowing back this. it is one of our most optimistic area. >> all right. thank you. we appreciate your clarity tonight. with tdr. >> drug stocks had a down day after president trump took twitter promising to cut the price of medicines. he said he is work on a new system. pricing will come way down. the president offered no specific buzz it was enough to extend shares of the biotech ticker symbol ibb by more than 1.5% the president has plenged to invest in infrastructure and to renegotiate trade disease and changes to eithe

are talking about opening up the industry for competition, getting rid of crony capitalism and big pharma being in bed with the government, find, the government has no business negotiating drug prices. the whole reason we had the epipen schedule with the price going up with a direct result of obamacare, people can't afford prescription drugs because their insurance doesn't kick in until they pay their $6000 premium or whatever. the federal government has no business directing, negotiating drug prices. >> the government can negotiate. it is a trade-off of what they want. let's take example denmark which pays a third of the prices for prescription drugs. what happens if we adopt that model with the buying power of medicare which we could do. the flipside is r&d to these companies would drop by 30% is where do we think the new drug come? not just from the us but the world rides on our pharmaceutical shoulders. you cut back on the r&d, you can pay less prices for the drugs but less new drugs coming it. >> you can lower prices, but you have less drug development. you want more drugs don't nego

senator paul was right, until you really transform things to cut undo the costs, whether that is pharma costs or malpractice or how we deliver care or who is doing it right or who is doing it wrong, at jefferson, liz, we're expanding telehealth, getting people out of the e.r., the way we get paid penalizes customers. liz: let me bring in president trump because right now is he expected to meet about certain members very much involved in the getting the votes. >> right. >> the vote will be tough. as soon as we get video to this, we will get it to you. important to say, president trump, right away as this thing was unveiled said, it is up for discussion. it is up for review. he has shown he wants to compromise on this. i would imagine i would like to hear from some democrats as well. now, they get to keep two of the things that were very important to obamacare for a lot of people. people with preexisting conditions would continue to be covered, they couldn't be dropped. young people up to age 26 could stay on their parents parents' plan. the freedom group appears to be intransigent. do yo

pharma is going to be opposed. the entrance industry, the most of us because it is life and death for them. said thise priebus week and that democrats, bring your proposals to us now. of civileing a kind war and the republican party. will we see the same in the democratic party? >> i am doubtful about that. certainly at this moment, the democrats as an opposition party tend to unify when they are actually running things, the divisions come out much more. amy: bernie sanders is part of the leadership. are you saying the leadership might endorse a medicare for a proposal yet though what does a public should proposal mean? >> the way the leadership can be brought to endorse single-payer is by us, the constituents. calling them up, pressuring them and all the ways that we have sent we want single-payer. that is what will bring the full democratic leadership around. public option? public option would be a small step that would ease some of the pain. it would mean when you are on the exchange buying things, one of your o

it would diminish trial studies, and that is going to impact pharma. facing opposition from democrats in washington and many republicans, who viewed this skinny budget as too few details and promising to do too much. another source of a committee member on the republican side told me this is going to dramatically change when we get to the final budget outline. vonnie: a couple of increases for fiscal, the supplemental part, but most departments with dramatic cuts. will democrats shut down government over this? kevin: am not sure they will be able to. withwould have to link some tea party members, but president trump signed to boost military spending by $54 billion. he will offset the increase by cutting several key agencies, and some business leaders view that as rolling back regulations and they like that aspect. infrastructure companies and companies to work involvement in infrastructure spending will get a boost because the skinny budget outline indicates they will be doubling down of partnerships with infrastructure. mark: thanks a lot, washington

what we saw with the pharma -- pharmaceutical company, it just transformed to the aerospace industry.onnie: what is the problem -- if the products are bought by the new administration, the pentagon, any number of foreign governments, what does it matter how much they jack up their prices? andrew: good question, and that is the key. first of all, let's say boeing. anyone who follows the aerospace business knows that boeing is becoming a lot more controlled with their supply chain. they are not just letting people jack up prices or raise prices and is currently on them. so, as boeing and airbus are becoming more controled, the company's more dependent on the department of defense. this is not a number they will release. i do not want to hear how much of your revenue is from defense. bida isrcentage of your e from defense? 20 we know about the government, it wears a blindfold and it has deep pockets, but when donald trump addressed congress and made a statement that we would renegotiate many government contracts, transdigm should be upset. the one person they should be of theed about, th

big cap pharma as well. think the drug pricing issue is off the table for the most part because of what they've come together on. i think it is very important to be in lien with the president the company that are have proven to be winners. >> when you think about what is the biggest deal ever that's on the table that needs to get approved or wants to be approved, it is the at&t time warner deal. if that happens, who do you think will be doing a deal? charter also. in some ways, it makes a lot of the sense. they are fiduciaries to their shareholders. i can't really argue with that behavior. let's see it for what it is. >> a little good will here. >> considering it is something that you already announced. >> totally. all these ceos have to do this and they will continue to do it. whether or not his quote under quote stock goes down. but the pipeline deal for me. it is old, stale. they've had pipelines around it. i think the saudi aramco is bought only. decleaning oil prices for that entire space will be contin

pharma topping this quarter, and qualcom the biggest loser in the ind index. >> down 11% in the quarteramazing. meanti meantime, twitter beef, wendy's throwing shade at mcdonald's after they announced yesterday by mid-2018 all quarter pounder burgers will be cooked with fresh, never frozen beef. shortly after that, wendy's responded on twitter with? so you'll still use frozen beef in most of your burgers in all of your restaurants? asking for a friend. shares of mcdonald's up 6% year to date. wendys a fraction of 1%. they got the best of them on that, but i, you know, i think mcdonald's is behind the curve there. vulnerable. wendy's for years and to some degree five guys proved you can serve fresh never frozen burgers. >> smash burger, and had panera's ceo on, they explored the menu 15 years ago, so mcdonald's is getting on the wagon. >> why only the quarter pounder? >> yeah. you got to start somewhere. >> i guess. >> this is why i love twitter, by the way, because only because of this could we see the two companies directly -- >> i mean, like the old coke-pepsi wars back in the day. >>

tobacco and soda and pharma. it was -- i didn't think in the beginning when it was raised as a way to fund pre-k that we would have been successful. >> you didn't think it would work? >> i was skeptical. but we worked very hard. we were very honest with our information. they were very dishonest. i didn't know if we would get nine votes to pass it. we got 13. i was very happy and thankful to counsel for their courage. they put up with a lot of stuff during the course of that campaign. during the course of the legislative fight. i get up every morning and i'm looking at negative ads from the soda companies than when i was running for mayor. they had the money. they can do what they -- try to do what they want. in the end, we had pre-k parents, advocates, people who wanted to see the rec centers restored. people committed to community schools. we had the grass-roots people. they paid. we had the regular people. >> have you talked to other cities? >> seattle is trying to do it now. albuquerque, new mexico. there's a

pharma. we should implement legal reforms that protect patients and doctors from unnecessary cost that drive up the price of insurance and work to bring down the artificially high price of drugs and bring them down immediately. >> reporter: since he was lekted, trump reiterated that he plans to bring drug prices down. >> the president gets criticized sometimes for inconsistencies. but he's been absolutely consistent about -- for over a year now, about wanting to do something about drug pricing. >> typically the comments focused on drug makers themselves. but last night in an interview on fox news, the president brought another party into the conversation. saying, "we have a middleman system. we're going to get drug prices so far lower than they are now, your head will spin". so who are these middle men? >> there's three elements. you have the distributors which are the box movers. they deliver the drugs around the system to pharmacies from the pharmaceutical companies. you have the pharmacy b

joe. >> president trump's regulation rollback will have a big impact on the pharma industry., founder of gene therapy company, myra gpx. did you found some other company? that's right. in clone as well. good to see you. >> good to see you. >> you're not herba tucks, what are they doing. >> millions. >> okay, great. so we've got trump. he's doing certain things in terms of regulation. you like scott gotly? >> i think scott gottlieb is an enormous plus for america. >> you've also got at least some talk about drug pricing that could bring pressure on in accelerators and possibly hurt innovation. you've got that. you're hot to talk about nih. any budget cuts for nih. you've got big problems with that? >> i do. >> net net is it positive or negative this presidency? >> we don't know what's going to happen. people look at regulation and health care differently than they look at regulation for everything else. you had richard lefrak on talking about rebuilding america's infrastructure regulation. i love richard. there people don't feel infrastructure is a right. everyone feels health

for thebig market pharma industry. >> the indian government has been desperate to curb the countriesnd during love for gold. imports have heard the ruby -- the ruby. the controversial ban on high denomination now seems to have. explain why the earlier program didn't work? >> the earlier program had problems in terms of the amount of gold that people had to deposit. now they have reduced the amount of gold you can deposit with the banks. another issue was getting the infrastructure in place. that was another challenge the government had to face in their buyingaking purchase. the price could be bigger than the fed hike. that is ahead. >> you are watching the best of bloomberg markets middle east. borrowers are selling bonds at an unprecedented pace. bond sales were above $100 billion this year ahead of the federal reserve rate hike. we spoke to someone at templeton investments. >> one has to recognize emerging markets in general are beginning to pursue more orthodox policies. we had a rebounding commodities. you see growth numbers improving generally speaking across the board. most of

meg tirrell looking at pharma and health care. >> we got some glimmers of what the white house wants to do with infrastructure. it's proposing to end several projects. the government's proposing steep cuts to infrastructure heavy agencies and their programs at agricultu agriculture, cutting rural water program. and a billion dollar budget cut at the defense department's corps of engineers which maintains inland water ways like dams and harbors. it proposes infrastructure funds increasing for cyber security and the nation's power grid as well. experts say the up side of having a white house centric infrastructure policy is it gives the administration bargaining chips for high agenda items lax tax reform. infrastructure is a lower agenda item. that's why you can see the infrastructure bellwethers have lagged the overall market. they're divided over this budget. this is far from a final draft so it's hard to say which companies are going to be fighting over some of these new projects and losing business over the projects that get cut. we'll have to see what makes it into the final draft

we have a large market for the pharma industry.so want to use it as a platform for exporting form of goods. >> the indian government has been desperate to curb their loss because record imports have hurt the deficit. persuasion did not work but the prime minister's controversial ban on high denomination notes seems to have. why that earlier program did not work yet go the earlier program had a lot of problems because in terms of the amount of gold that people had to deport was too high and indian households didn't have that much but now they have reduced the amount of gold you can deposit in the bank. the other issue was getting the infrastructure in place because indians do not have a lot of -- the rural population doesn't have access to bank accounts, so that is another challenge, in addition to making them [indiscernible] -- at why the look falling oil price could be a bigger threat to emerging-market debt then the fed hike. ♪ >> welcome back. , bill chance of going through his proposal to cut funding to boost defense spending e

been eight that problem for the japanese pharma. -- a problem for the japanese pharma.k at the movers in tokyo. we have toshiba rising over 3%. toshiba officials say the company is on track to report earnings by march 14 and says the deadline for bids for the chip unit is in talk with funds as the most likely buyers. face regulatory hurdles. it is the worst performer on the nikkei 225 year to date. in sydney, shares a dragged lower by minors and property stocks. falling 6%, down for a second day. this is the government is set to invest aussie dollar's into the clean energy fund to be carbon neutral by 2030. we have gold miners resolute, up here tracking bullion's gained. we saw the stock illustrating resilience this week, and take a look at the korean won as china expresses its displeasure over the sad issue. the korean won has seen a large interior ration of the fundamental trade, diminishing since last january. pmi has been a contact larry -- has been in contractionary territory. the negative turn is not yet extreme enough for risk to be seen as bearish. the finance m

we thought it would drive genegh big pharma or the companies. that totally took us by surprise. often we do not know what the business model is going to be that really drives the technology. host: one more call from timothy in vermont. caller: yes, good morning, gentlemen. like to digress a little bit, but two words come into my mind -- three. fukushima and the pacific ocean, and there is so much hot water barely going into the pacific ocean in that ocean is literally dying. is there anys applied technologies or anything to possibly -- this is a disaster, and no one ever talks about it. briefly abouttalk nuclear power and then i will talk about the acidification and warming of oceans. i think nook power is potentially -- nuke power is a potentially important source of carbon and neutral scalable technology, but you are right that the technologies we have for reactors at the moment are incredibly expensive and not very safe and rely upon the fuel cycle of enriched uranium, what .e use for weapons what we want our reactors, like or molten salt, reactors, that are smaller, safer, a

>> it is interesting that pharma companies who sell opioids have opposed the very strongly. they think it would help. marijuana has been realized as being legalized and opioids are less serious. here's a technical point that i am not a doctor. what seems to happen is people get addicted. no one knows how to get someone addicted. addicted. -- unaddicted. that is a very strong statement. they get themselves unaddicted. they relapse. if you relapse and you take the dosage you were taking just diere you relaxed, you will . that is what you need to control your pain. , you mayke marijuana get addicted to marijuana but it does not do that to you and it is like alcohol. you may be addicted to alcohol, you may go on the wagon. if you fall off the wagon you're not going to die. you would just be drinking again. that is how it kills people. >> have you thought about the influence of unemployment falls having a negative psychological effects? >> there is quite good literature associating unemployment with mortality. several years later and in this age group. you get unemployed when you

it is not a big deal for pharma. the insurers are in wait and see mode.rms of what the regulatory environment will be like for them. mark: what are the other sectors we should be keeping an eye on? three -- there the hospitals seem to be where the action is. they are trading in line with whatever the latest twist and .urn down in washington is they were up slightly this morning fo. they will gyrate along with that. that is where i would keep my eye in the short-term. in the long-term, this is one step in a long, messy, difficult legislative process. we will be going through this for quite some time once we get to the senate where it is even harder. mek: this is what intrigues -- even if you get through today, you say there is a massive hurdle in the senate. will that be the ultimate stumbling block? >> yes. ultimate stumbling block number one. the senate will change the bill substantially to get it through. it tends to be more moderate. the process right now is to appease the conservatives in the house. then they will have to get back and agree somehow on

it was a big day for pharma industry on tuesday.their plan to replace obamacare and trump tweet,arma lower with a "i'm working on a new system where competition for the drug industry what prices for the african people going way down." we did see this movement and .harma stocks was it the trump tweet or the republican plan or both? >> i think of as much more of the trump tweet. the republican plan was not too bad from the farmer perspective. -- the form of perspective. -- the pharma perspective. there was nothing with pricing in the plan, but trumps tweet right after the plane came out told investors the big issue is not going away and we are in a theyng period to see how address the issue of drug prices. david: we've not seen the plan on addressing drug prices yet. to be have any indication of how they might go about that? they will not have direct regulation of prices i assume. vamil: some of things that trump has mentioned himself is the government having one negotiating power when they set prices with the drug companies. could th

vonnie: specialty pharma?er area where we have nibbled on the bond side and have been shorting on the equity side. favor, in get out of this environment, they can fall to $.30 or $.40 on the dollar. we are doing some capital arbitrage. long on the bonds, short a little equity, so one of the two is mispriced. geographically, any interest in europe? at thisfortunately, not point. we still see the best value in the u.s. and smaller, more often the run names. and haven'turope really found anything as attractive at this point. we have tof peskind leave it there. great performance last year and continued success in 2017. mark: coming up, general motors -- selling itsopel its opel unit. we will tell you why. this is bloomberg. ♪ vonnie: you are watching bloomberg. i'm vonnie quinn. mark: and i'm mark barton. here's your global business report. the deutsche bank chief executive is pairing up his own turnaround plan after less than a year and half. find out what he told bloomberg about his new strategy. official, gmt i

so did pharma stocks, they plunged, allergan, pfizer and mylan. >>> this bronze little girl showed upsly stare down the iconic bull. she captivated tourists downtown but who put her there? turns out state street global advisers is behind the statue entitled fearless girl. it's no coincidence that today is national women's day. the ceo says in a statement the company is calling for more women on their clients corporate boards. they have 3,500 companies that they invest in. and they want to see more women on the boards. saying women are key to that success. women account for only 16% of all corporate board seats among the largest u.s. companies. that's according to the government accountability office. dave, there are sorry studies that show where there is strong leadership in companies. and women on the boards, they have higher returns than companies that have -- sort of the less diversity of opinion. >> 16%. that's nationwide or in the world? >> 16%. of the largest yet. >> staggering statistic. >> scandinavian countries do very well. >> one would you assume it would be higher than 16%